Previous 10 | Next 10 |
Plus Therapeutics press release ( NASDAQ: PSTV ): Q3 GAAP EPS of -$0.19 beats by $0.02 . Revenue of $73K. The Company’s cash balance was $20.3 million at September 30, 2022, compared to $18.4 million at December 31, 2021. For further details see: P...
Awarded $17.6 million Product Development Research grant by the Cancer Prevention & Research Institute of Texas (CPRIT) to fund 186 RNL development for leptomeningeal metastases (LM) Completed cGMP manufacturing objectives to support Phase 2 clinical trials for ...
Plus Therapeutics ( NASDAQ: PSTV ) is scheduled to announce Q3 earnings results on Thursday, October 20th, after market close. The consensus EPS estimate is -$0.21 . Over the last 3 months, EPS estimates have seen 0 upward revision and 2 downward revisions. F...
ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and all patients showed a decrease in spinal fluid tumor cell counts ReSPECT-GBM Phase 1 clinical data selected as Top-Rated Oral Pres...
AUSTIN, Texas, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, announced today that Marc Hedrick, M.D., President and Chief ...
Cheap Penny Stocks To Buy Penny stocks generally trade for $5 per share, which makes them some of the most appealing for new or novice traders. The ability to purchase hundreds, thousands, or even millions of shares for a couple of hundred dollars gives way to scoring big when stocks ex...
Nano-cap biotech Plus Therapeutics ( NASDAQ: PSTV ) gained ~18% pre-market Friday on rising volumes after financial brokerage JonesTrading started its coverage with a Buy rating on the potential of the company’s lead asset Rhenium-186 NanoLiposome. 1.6M PSTV sha...
AUSTIN, Texas, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will ...
AUSTIN, Texas, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Dr. Andrew ...
AUSTIN, Texas, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will ...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...